Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug

Aardvark Therapeutics is currently facing a full FDA clinical hold on its drug intended for treating Prader-Willi syndrome, a rare metabolic disorder characterized by excessive eating. This hold follows a voluntary pause earlier this year due to cardiovascular issues observed in a healthy volunteer during trials. The company is now exploring options to move forward despite these regulatory challenges.